Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP +2.50%89 Intrinsic Value: Projected FCF is A$1.10 as of Jul. 31, 2026, which is 100% below its 10-year median of 2.96. GuruFocus rates ASX:AFP with a GF Score™ of 89/100 and a GF Value™ of A$3.42 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 634 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 83.12% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-07-31), AFT Pharmaceuticals's Intrinsic Value: Projected FCF is A$1.10. The stock price of AFT Pharmaceuticals is A$4.10. Therefore, AFT Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 3.7.
The historical rank and industry rank for AFT Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:
ASX:AFP'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.81 Med: 2.96 Max: 17.3
Current: 3.73
During the past 11 years, the highest Price-to-Intrinsic-Value-Projected-FCF of AFT Pharmaceuticals was 17.30. The lowest was 1.81. And the median was 2.96.
ASX:AFP's Price-to-Projected-FCF is ranked worse than 83.12% of 634
companies
in the Drug Manufacturers industry
Industry Median: 1.535
vs ASX:AFP: 3.73
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
AFT Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
4.10
/
1.086309524132
=
3.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals Intrinsic Value: Projected FCF Related Terms
AFT Pharmaceuticals Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AFP vs ZTS, UTHR, VTRS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of A$1.10 mean?
AFT Pharmaceuticals (ASX:AFP) has a Intrinsic Value: Projected FCF of A$1.10 as of Jul. 31, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on AFT Pharmaceuticals and its competitors. This is 63% below median its historical median of 2.96. Over the past decade, AFT Pharmaceuticals' Intrinsic Value: Projected FCF has ranged from 1.81 to 17.30. According to the industry distribution chart, AFT Pharmaceuticals ranks #527 out of 634 companies in the Drug Manufacturers industry, placing it in the top 83.1%.
Is AFT Pharmaceuticals' Intrinsic Value: Projected FCF too high?
AFT Pharmaceuticals' current Intrinsic Value: Projected FCF of A$1.10 is 63% below median its 10-year median of 2.96. Over the past 10 years, this metric has ranged from a low of 1.81 to a high of 17.30. Based on the distribution chart, AFT Pharmaceuticals ranks #527 out of 634 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Intrinsic Value: Projected FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #527 out of 634 companies for Intrinsic Value: Projected FCF. This places AFT Pharmaceuticals in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.54. Historically, AFT Pharmaceuticals' own Intrinsic Value: Projected FCF has ranged from 1.81 to 17.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.54, based on 634 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Intrinsic Value: Projected FCF is A$1.10, which is 63% below median its own 10-year median of 2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Modestly Overvalued. The stock's GF Value™ is A$3.42, compared to a current price of A$4.10 — trading 19.9% above its estimated fair value. The current Intrinsic Value: Projected FCF is A$1.10, which is 63% below median its 10-year median of 2.96. AFT Pharmaceuticals' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Intrinsic Value: Projected FCF is A$1.10 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be overvalued.
The current stock price of A$4.10 is trading 19.9% above its estimated GF Value™ of A$3.42.
GuruFocus considers AFT Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ASX:AFP:
Intrinsic Value: Projected FCF: A$1.10 (63% below median its 10-year median of 2.96)
GF Value™: A$3.42 vs. price of A$4.10 (19.9% above fair value)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
89GF Score
Get the complete analysis for ASX:AFP
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
